Drugs / MyoPAXon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06692426 | Mar 2025 → Mar 2027 expected | Duchenne muscular dystrophy | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MyoPAXon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06692426 ↗ |
| Modality | Cell therapy | “MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2” NCT06692426 ↗ |
| Route | Intramuscular | “MyoPAXon will be delivered via open intramuscular (IM) injection into a single EDB muscle for each participant as a one-time dose” NCT06692426 ↗ |